Veloxis Pharmaceuticals, Inc entered into a global license agreement to acquire Worldwide Rights to FR104 from OSE Immunotherapeutics SA (ENXTPA:OSE) on April 26, 2021. Pursuant to the transaction, OSE Immunotherapeutics will receive up to 315 million in potential milestones from Veloxis, including a 7 million upfront payment.
Market Closed -
Other stock markets
|
After market 03:27:32 pm | |||
5.52 EUR | -0.72% | 5.515 | -0.09% |
Apr. 17 | OSE: licensing agreement with AbbVie enters into force | CF |
Apr. 17 | OSE Immunotherapeutics Finalizes Drug License, Collaboration Deal With AbbVie | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+28.97% | 128M | |
+1.53% | 42.75B | |
+47.70% | 41.61B | |
+11.92% | 41.34B | |
-8.83% | 26.59B | |
+6.50% | 25.49B | |
-23.37% | 18.12B | |
+29.87% | 12.24B | |
-2.42% | 11.76B | |
+7.94% | 11B |
- Stock Market
- Equities
- OSE Stock
- News OSE Immunotherapeutics
- Veloxis Pharmaceuticals, Inc entered into a global license agreement to acquire Worldwide Rights to FR104 from OSE Immunotherapeutics SA.